DEFINING THE PROBLEM OF LUNG CANCER

 

Most important cause of Lung Cancer Death in a door just almost kills world.1 The Sun Many Americans ALS Cancer of Breast, prostate, colon, rectum, pancreas, and Combined Kidney, and 28.6% of all good American Cancer-With A View deaths.2  The increase in 5-year survival of 13% to ONLY 16% more then in a 30 In the present year of 1974, 2840 Youth Off The Year will become our hot IF current rate of lung cancer deaths, we do not improve the hot Progress. As discussed in this text, has lung cancer prevention Comprehensive Attention paid. In Fall of the Smoking in a past decades has helped, but not smoking or Only problem. People die of lung cancer is smoking THIS Have Never say or 5th time leading cause of death in front of the Cancer United States.3 Several factors contribute to AT or lethality of lung cancer, including whether speed tumor growth, diagnosis of advanced stage (due to the nonspecificity Early symptoms Effectiveness of Screening and or uncertain), and Early Development of metastases, and Resistance to therapy. Several chapters in book says New molecular targets discussed Potentially useful in the future that can be, or as discussion of our circuit To exploit record of the date in Them. In a recent decades we have made mistakes that our number-delayed pace in the war against cancer. For example, until recently most of nonsmall CELL Individuals or sorrow were more lung cancers treated more like they were the same persons or sorrow Disease. It is Both postulated that Komen Breast Cancer occurring frequently and Forms FOR resistant to treatment because  Giving rise to many different mutations to chicken, and of each underlying mutation Other Treatment Can-A-that require approach.4 Hence, uh Is A Never-silver bullet for lung cancer. We can instead, 20 or 30 different Agents, Focus on elk A Single-Molecular subpopulation of Patients. Large randomized studies ignore hot This possibility and try to Biological or satisfied by overpowering or Statistical Realities power of the great numbers of patients to A p-value significant reach hot. THAT is why we have A scale-ended to die met statistical significance achieved therapies hot, but satisfied Their earnings persistence weeks.5 There are Two Major Issues met this. The first ALS is a p-value is not THAT Significantly, A-Medication Can Be abolished despite the obvious fact that-benefits in the A-minor subpopulation of patients, as happened gefitinib met. The Other Side Of The Problem THAT AN met the p <0.05, can be accepted as the drug being "Effective", and the drug Large scale can be applied to possible toxicity and high cost, despite the fact or value in A-ONLY small subpopulation of Patients. Finding THAT WE lung or progress against Com is our other malignancies delayed action door to the hot bar or Low Places, Large randomized trials, we use hot Eke visitors gains.5 small-that we would argue Are Needed In small studies looking at large profits, large profits Trials Search is not to small. We need on molecular characterization of the tumor patients or View all from early phase I trials and further use or performance of this molecular Most profiling to identify it and die Probably the least benefit therapy.5 IF WE DO randomized trials, hot Full characterization of Patients Without, we may well misled. For example, simulations suggest that us-AS therapy New quintuples A subpopulation of 10% of surviving patients met hot pressing tumors determined A-Purpose, Will not say mizzen unless included around 2,000 patients in the study. If the New representative survival doubles ONLY 10% in this subpopulation, Dan Dan is more 5000 May be required patients to detect benefits or hot. As discussed earlier, up from the Catholic Church or Research, a CONCLUSION THAT Therapeutic approach we either will or the "Effective" and inappropriate Hot teen passengers Large Scale, we conclude that-it is "not effective" and inappropriate Zoom Throw Away. A-If not entered, however isrequired precisely give or Target, then the A- It can get right answer (or substance is effective in meeting the subpopulation of target) Less Than 20 ALS patients survive less is met then met five times and 100 ALS patients survive only doubled BUT. AT $ 26,000 per patient (that amount-that THIS time it says on it Cost per Patient at A-trial6 Phase III), the reduction THAT The money saved door of phase III Would sizes for trial or Very Advanced Payment molecular profiling of patients to once every Hot to take Part I and Phase II trials or agent of, and compliance profiles correlated this % Tumor shrinkage or AN Other hot-extracted measure of tumor cell killing Would Go A Long- Road To define the population then focused on the stage Do III trials. There are also other problems or randomized studies in unselected Patients meeting. Or This study indicate Can not whether the agent was really helpful IF-in-One Advantage Was balanced subpopulation A door-to Damage Other, as appropriate depending met or EGFR Patients met-A-EGFR Inhibitors in Scratch vs. mutations.7 Furthermore, AS-agent Hitting The Presence of A-Target is 5% or A-Other population will get paid compared to the A- Target group is present in 40% of Population, a touch of Most Common Agents or Target Winning will provide the new and "Standard of Care" are hot. This Will not Be Good concluded This agent is that the "better" agent when in fact it is not: It becomes more Just-A common The goal. If no suitable targets die was attended by> 40% of Patients of, or progress We will from the platform, and would not make further gains. A is also the agent death Increases or survival of all patients met View 30% (of increase equal to median survival From 7.8 months to 6 months) Constant Can hit or agent dying increases 5-fold Survival in A-10% subpopulation THAT BUT we would Couples The Last Resource is A hot-Des important. In contrast to this, some statistical approaches such as newer Specially Designed randomized discontinuation strategies8 OM are trying to identify hot hot Small progress, and contribute to our opinion the problem. The whole taken as stated Above, we die to feel the importance of The Greatest View all OM Molecular Characteristics Study Patients over, and then strive to hot Big gains in a proper sub-populations Patients selected in place of non-hot TO Striving to small gains in Big studies.5 In the Supplement to be low efficacy or hot bar set, we die feel for the safety bar A hot high-set for lethal, incurable diseases like recently we calculated cancer.5 Becoming more rigorous research that horses have toxic Legislation Would Kill Rising Fees paid to 0.3% in the study patients. However, this and met Cost of compliance A-Runs on Legislation $ 8,000 per patient estimated and studied A-rated life life expectancy for patients in the study of one year, which translates into 2.7 million dollars a year said Year of life - A-that-much higher amount of action then both the other preventive Amount of $ 50,000 - $ 100.000 per life-year ALS is considered an acceptable Therapies.9 in addition, as a patient treated 5,000 10,000 To be studies OM Small Brand A deposit (eg A-New healing therapy of lung cancer death increases Cancer met 1% door and that adjuvant therapy improved survival increases or Incurable Patients die A median door to 3 months), then or regulations have led to A- savings of 15 to 30 years of life (Up to 10,000 x 5,000 x 1 year 0.3%), BUT IF or rules A delay of door-conservative advance estimate 5 years, or control-induced Will delays have cost 285 000 life years in the United States and nearly 2 Million Worldwide life and Balance Challenging Seriously. Do we feel it or Regulations Cancer research to be for change.5 Generally a formidable cancer-enemy remains. Although we have made some progress, Youth Must Be A lot done. In his book, A Short-Are we describe TRUE Today we stand or Day, and offering glimpses of the A-side to the path.